Wegovy Maker Novo Nordisk’s Stock Rebounds After Q2 Miss, But Retail Investors Stay Cautious

U.S. shares of Novo Nordisk (NVO), the Danish healthcare giant, are rebounding on Thursday. This follows a steep 8% drop triggered by a disappointing Q2 report on Wednesday. But retail investors are not jumping on the optimism bandwagon yet.

While Novo Nordisk's Stocktwits sentiment initially dipped to its lowest level in a year before the opening bell, it quickly recovered to 'neutral' territory (50/100).

Lower-than-expected Q2 profits and a trimmed operating profit outlook are causing some concern. Despite a 55% surge in sales for its popular weight-loss drug Wegovy, Novo missed analyst expectations.

Competition is heating up from smaller companies like Altimmune and Viking Therapeutics, as well as giants like Eli Lilly and Pfizer, prompting concerns from some bearish retail investors.

“Wegovy sales down because $HIMS and other competitors reducing cost for consumers and seeing increase in subscribers,” read one post on NVO’s Stocktwits stream.

Others highlighted concerns over high valuations and the threat of future, AI-driven drugs from competitors. 

However, there are bright spots. Wegovy's recent approval in China opens the door to the world's second-largest economy. Additionally, the U.K. and E.U. have reportedly backed the drug for reducing heart disease risk in overweight adults.

CEO Lars Fruergaard Jørgensen remains optimistic, projecting "attractive growth" in the coming months, which reflected in the overall market sentiment as shares rose 3.61% to $123.53 early on Thursday. Retail investors, however, are adopting a wait-and-see approach.

One bullish post also emphasized the company's broader portfolio beyond Wegovy, suggesting that Novo Nordisk's pipeline remains strong.

The future performance of Europe’s most valuable listed company hinges on navigating competition while delivering on its CEO's promise. Retail investors for now remain cautious until they see concrete evidence of this growth.

Share

·

Add us on